MICHELLE DIPP, M.D., PH.D.
Chief Executive Officer and Co-founder
Dr. Dipp is the founding Chief Executive Officer of OvaScience and serves on the Board of Directors. Dr. Dipp is also a Founder and Partner of Longwood Fund, a healthcare investment fund. Previously, Dr. Dipp was the Senior Vice President and Head of the CEEDD at GlaxoSmithKline. Prior, she was Vice President of Corporate Development at Sirtris prior to its acquisition by GSK. Before joining Sirtris, Dr. Dipp worked in healthcare private equity at The Wellcome Trust, London. Dr. Dipp serves on the Biotechnology Industry Organization’s (BIO) Emerging Companies Governing Board, the New England Venture Capital Association (NEVCA) Board, the Beth Israel Deaconess Medical Center Board of Directors, the Boston Symphony Orchestra Board of Overseers, and the MassBio Advisory Board.
Dr. Dipp holds an M.D. and a Ph.D. from the University of Oxford.
ARTHUR TZIANABOS, PH.D.
Dr. Tzianabos is President of OvaScience. Prior to this role, Dr. Tzianabos was Chief Scientific Officer at the Company. Dr. Tzianabos brings to OvaScience more than 20 years of experience in drug discovery and development, strategic planning, portfolio management, business development and alliance management. He joined OvaScience from Shire, where he served as Senior Vice President and Head, Research and Early Development. During his eight years at Shire, he served in roles of increasing responsibility and was instrumental in the development of the human genetic therapies pipeline following Shire’s acquisition of Transkaryotic Therapies, Inc. in 2005. He also played an active role in the development, approval, and commercial launch of several therapies for the treatment of patients with rare diseases. Prior to Shire, Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. A major focus of his research was on the development of therapies for the prevention of adhesion formation, a major cause of female infertility. During his time at Harvard, Dr. Tzianabos served as a consultant to several biotechnology companies, including Genzyme Corporation and Eli Lilly. Dr. Tzianabos has published more than 80 scientific papers, reviews, book chapters, and patents. He continues to advise and serve on the Boards of several biotechnology companies.
Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.
EVP, Global Site Operations
Mr. John Eisel is the Executive Vice President of Global Site Operations. He joined from InnerWorkings LLC, where he served as Chief Operating Officer since 2011. Prior to that, he was Divisional Vice President of Strategic Operations, Pharmacy Services for Walgreens, where he designed and led operations strategy for the more than $40 billion pharmacy business. He also held roles of increasing responsibility at McKinsey & Company, including serving as Associate Principal. Mr. Eisel began his career at PricewaterhouseCoopers, serving as a Senior Associate in Financial Advisory Services.
Mr. Eisel is a Certified Public Accountant and holds a B.S. in Accountancy from the University of Illinois at Urbana-Champaign and an M.B.A. from Northwestern’s Kellogg School of Business.
Chief Commercial Officer
Mr. Harding is the Chief Commercial Officer at OvaScience. He joins OvaScience from Hologic, Inc., where he most recently served as Group Senior Vice President and General Manager of Women’s Health and was responsible for the global business for multiple product lines, including the sales and marketing functions. While at Hologic, he held roles of increasing responsibility, including serving as Senior Vice President, International, and Senior Vice President and General Manager, Interventional Breast Solutions. Prior to Hologic’s acquisition of Cytyc Corporation, Mr. Harding was Senior Vice President and President of Cytyc International. Earlier in his career, he was an associate and then partner at McKinsey & Company.
Mr. Harding holds a B.S. in Aerospace Engineering from the University of Southern California, and an M.B.A. from the Wharton School of Business at the University of Pennsylvania.
EVP, Chief Communications Officer
Ms. McNeely is Executive Vice President, Chief Communications Officer at OvaScience. Prior to this position, Ms. McNeely was OvaScience’s EVP, Strategic Corporate Communications. Ms. McNeely has over 20 years of integrated Corporate Communications experience spanning Investor Relations, Public Relations, Marketing Communications, and Patient Advocacy in Life Sciences companies, including pharmaceutical and biotech, molecular diagnostics, tools and service providers. She has counseled executive teams on communications strategies around key events, such as international product launches, clinical trial results, strategic redirection, executive transitions, and regulatory decisions. Prior to OvaScience, Ms. McNeely was Vice President of Corporate Communications at Clinical Data, Inc., a company that developed and obtained FDA approval for a new antidepressant which led to its acquisition by Forest Laboratories for $1.2 billion. Ms. McNeely has held management positions at Millennium Pharmaceuticals, EXACT Sciences and Pyrosequencing. Earlier in her career, Ms. McNeely worked on Wall Street for a boutique investment bank. She is an advisory board member for Cramer, a creative marketing studio.
Ms. McNeely received her B.S. in Business Administration from Providence College, and an M.S. in Business Communications and Healthcare Communications from Simmons College.
RAVI MEHROTRA, PH.D.
Chief Corporate Development Officer
Dr. Mehrotra is the Chief Corporate Development Officer at OvaScience. He joined from Credit Suisse LLC where he served as Global Head of Biotechnology Equity Research since 2010 based in New York, leading the equity research team that covered more than 40 global biotechnology and life sciences companies. Dr. Mehrotra originally joined Credit Suisse in 2004 in London, U.K., and served as Head of European Biotechnology and EMEA Equity Research, being ranked the number one analyst in both European Institutional Investor and Extel surveys. Prior to that, he held positions of increasing responsibility at SG Cowen in London, including Head of European Biotechnology. Earlier in his career, he worked for Deutsche Bank (Natwest Markets/BT Alex Brown) in London.
Dr. Mehrotra holds a Bachelor of Science in Biochemistry and a Ph.D. in Biochemistry and Molecular Biology from Manchester University.
Chief Financial Officer
Mr. Jeffrey Young is the Chief Financial Officer at OvaScience. Mr. Young joined OvaScience from Transmedics, Inc., where he served as Chief Financial Officer and Treasurer, leading the finance, accounting, tax and treasury functions. Prior to Transmedics, Mr. Young was CFO and Treasurer at Lantheus Medical Imaging, Inc. While at Lantheus, an international corporation, he was responsible for multiple functions, including finance, accounting, customer service, tax and treasury. He also assisted in raising $400 million in a registered notes offering. Before Lantheus, Mr. Young served as Chief Accounting Officer, Vice President of Finance and Treasurer at Critical Therapeutics, and managed the company’s transition during its acquisition by Cornerstone BioPharma. Earlier in his career, Mr. Young held finance roles at PerkinElmer, Inc. and PricewaterhouseCoopers.
Mr. Young is a Certified Public Accountant and holds a B.S. in Business Administration from Georgetown University.